Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 18/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6030737 | 0.87 | OPRD1 (0.55) | OPRD1OPRK1OPRM1HRH1 | |
| SCHEMBL6031570 | 0.79 | HRH1 (0.50) | OPRD1OPRK1OPRM1HRH1APP | |
| SCHEMBL6031686 | 0.78 | SIGMAR1 (0.55) | — | |
| SCHEMBL6030048 | 0.76 | SIGMAR1 (0.43) | HRH1 | |
| SCHEMBL7895228 | 0.75 | OPRD1 (0.47) | OPRD1OPRK1HRH1 | |
| Iodide SCHEMBL6031820 | 0.75 | SIGMAR1 (0.56) | OPRD1OPRK1HRH1 | |
| Isopropyl Alcohol SCHEMBL6101083 | 0.75 | SIGMAR1 (0.39) | HRH1 | |
| SCHEMBL6031086 | 0.75 | HRH1 (0.54) | OPRM1HRH1 | |
| SCHEMBL6030987 | 0.75 | SIGMAR1 (0.53) | OPRD1OPRK1 | |
| SCHEMBL6031884 | 0.74 | SIGMAR1 (0.37) | HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148214-B1 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-12 | — | — | US | disclosed |
| US-7087595-B2 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-08 | — | — | US | disclosed |
| EP-1144411-B1 | ANTIHISTAMINIC SPIRO COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2005-04-27 | — | — | EP | disclosed |
| US-20050026901-A1 | Antiallergens; vision disorders | JANSSENS FRANS EDUARD (BE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026901-A1 | Antiallergens; vision disorders | UACA, LTB4R, HLA-B | OPRD1 1139/4885OPRK1 2005/4885OPRM1 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.